Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $23.1 million.

  • Dare Bioscience's Cash & Equivalents rose 10565.12% to $23.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 10565.12%. This contributed to the annual value of $15.7 million for FY2024, which is 4984.81% up from last year.
  • Latest data reveals that Dare Bioscience reported Cash & Equivalents of $23.1 million as of Q3 2025, which was up 10565.12% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Dare Bioscience's Cash & Equivalents registered a high of $51.7 million during Q4 2021, and its lowest value of $3.6 million during Q1 2024.
  • Over the past 5 years, Dare Bioscience's median Cash & Equivalents value was $15.7 million (recorded in 2024), while the average stood at $21.2 million.
  • As far as peak fluctuations go, Dare Bioscience's Cash & Equivalents soared by 100663.78% in 2021, and later plummeted by 8161.2% in 2024.
  • Over the past 5 years, Dare Bioscience's Cash & Equivalents (Quarter) stood at $51.7 million in 2021, then tumbled by 32.91% to $34.7 million in 2022, then tumbled by 69.78% to $10.5 million in 2023, then soared by 49.85% to $15.7 million in 2024, then soared by 47.15% to $23.1 million in 2025.
  • Its Cash & Equivalents was $23.1 million in Q3 2025, compared to $5.0 million in Q2 2025 and $10.3 million in Q1 2025.